Hugel Wins Botulinum Toxin Lawsuit Against Medytox

Hugel has won the final ruling in the botulinum toxin-related lawsuit it faced against Medytox in the United States International Trade Commission (ITC). The ruling clears Hugel of allegations that it had stolen Medytox’s botulinum strain, reducing the risks to its U.S. market entry.

On the 10th (local time), the ITC concluded its review, determining that Hugel did not violate the U.S. Tariff Act. This ruling brings an end to the lawsuit filed by Medytox in 2022, which alleged that Hugel had stolen its botulinum toxin strain.

Medytox had previously claimed that Hugel violated Section 337 of the U.S. Tariff Act, which deals with unfair trade practices and intellectual property infringement, and demanded that Hugel’s products be barred from entering the U.S. market.

In a preliminary ruling on June 10, the ITC had ruled against Medytox, stating that there was no violation of U.S. customs law related to Hugel’s botulinum toxin products or their manufacturing processes.

Despite Medytox’s request for a review and oral argument, the ITC ultimately found insufficient evidence that Hugel had stolen Medytox’s botulinum strain. The commission also denied Medytox’s request for an oral hearing, bringing the case to a close.

A Hugel representative stated, “The final ruling has cleared uncertainties surrounding our U.S. operations. Hugel will continue to strengthen corporate credibility and shareholder value while pursuing continuous growth in global markets, including the U.S.”

In contrast, Medytox expressed dissatisfaction with the ruling, stating, “We believe the ITC’s decision is deeply flawed. We will review our options and take all necessary actions to uncover the truth.”